CJC-1295 No DAC

CJC-1295 No DAC Peptide Detailed Overview

CJC-1295 No DAC is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C152H252N44O42
Molecular Weight	3367.9 g/mol
Assay Purity	>98.5%
Appearance	Lyophilized solid

Figure 1: Conceptual Binding Mechanism of CJC-1295 No DAC

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. Without the DAC matrix, the peptide acts entirely as a pure GHRH analogue.
2. Possesses a short active half-life of roughly 30 minutes in vivo.
3. Attaches to the pituary GHRH receptor.
4. Creates a massive, naturally pulsatile spike in endogenous GH immediately following administration.
5. Rapidly degrades, perfectly simulating natural juvenile GH pulses.

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: Referred to heavily in biological chronotherapy (timing injections before sleep).
• Trial Output: When stacked with a GHRP, provokes a profound synergistic GH release.
• Diagnostic Core: Maintains absolute pituitary sensitivity by avoiding prolonged receptor agonism.

Modified GRF(1-29): Pulsatile GH Release

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is the same 29-amino acid modified GHRH peptide as CJC-1295 with DAC but without the Drug Affinity Complex conjugation. This produces a fundamentally different pharmacokinetic profile: a half-life of approximately 30 minutes rather than 8 days. The short half-life means Mod-GRF produces discrete, physiological-style GH pulses rather than sustained elevation, more closely mimicking the natural pulsatile GH secretion pattern regulated by the hypothalamic GHRH/somatostatin interplay.

1. Mod-GRF binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, activating Gs-coupled cAMP/PKA signaling.
2. PKA phosphorylation opens voltage-gated calcium channels, triggering GH vesicle exocytosis within 15–30 minutes of administration.
3. The resulting GH pulse peaks at 30–60 minutes and returns to baseline within 2–3 hours, mimicking a natural nocturnal GH pulse.
4. The four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) prevent DPP-4 degradation that would otherwise cleave native GHRH within 5 minutes.
5. Pulsatile GH release maintains GH receptor sensitivity and preserves the physiological GH/IGF-1 feedback loop, unlike continuous GH elevation.

Pulsatile Research Advantages

• Physiological Pattern: Discrete GH pulses more closely replicate natural secretion than DAC-conjugated continuous release, which may preserve tissue sensitivity to GH signaling.
• GHRP Synergy: Mod-GRF is almost always combined with a GHRP (ghrelin mimetic) such as Ipamorelin or GHRP-6. The combination produces GH pulses 3–5x greater than either peptide alone.
• Timing Flexibility: The short half-life allows precise timing of GH pulses (pre-sleep, post-exercise) to align with physiological windows of GH utility.
• Feedback Preservation: Unlike DAC versions, Mod-GRF preserves somatostatin-mediated negative feedback, preventing excessive GH/IGF-1 elevation.
• Dosing: Typical research dose: 100 μg SC, 1–3 times daily (commonly pre-bed). Always combined with a GHRP for maximum GH pulse amplitude.